Monitoring for ESR1 mutations in hormone-sensitive advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial checks whether routine blood tests can detect a specific genetic change (ESR1 mutation) that may make hormone therapy less effective over time. It is for people whose cancer is stable while taking a standard first-line treatment, and the results may help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced breast cancer that is hormone receptor-positive (ER+ and/or PR+) and HER2-negative
- You have been taking an aromatase inhibitor (like letrozole, anastrozole, or exemestane) combined with a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib) as your first treatment for advanced disease
- Your cancer has not progressed (grown) while on this treatment for at least 6 months and no more than 18 months
- You can give a blood sample every 3 months for genetic testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
This study looks for changes in the ESR1 gene in the blood of people with advanced HR+/HER2- breast cancer. It compares these blood test results with tumor tissue results to learn more about the cancer.
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
This study looks at whether a simple blood test can help doctors see how well treatment is working for advanced breast cancer that has stopped responding. It may help guide future care.
This study looks at whether a simple blood test (ctDNA) can tell if your current hormone therapy is starting to stop working, and whether switching to a different hormone therapy early would be better. It aims to keep your cancer under control longer with fewer side effects.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.